R. Katie Kelley, MD: Why Choose Durvalumab + Tremelimumab for the Treatment of uHCC?

Dr. Kelley explains when to choose durvalumab plus tremelimumab for your patients with unresectable hepatocellular carcinoma (uHCC). She provides an overview of efficacy and safety data from the HIMALAYA trial, as well as real-world data, which includes patients who did not fit HIMALAYA trial criteria. Finally, she discusses scenarios wherein the STRIDE regimen is a good fit for patients with uHCC.

Topics Covered

Long-term efficacy and safety data from the HIMALAYA trial
Real-world data on the efficacy and safety of durvalumab plus tremelimumab
Recognizing when the STRIDE regimen is a good fit for your patients

MORE EXPERT PERSPECTIVES IN GASTOINTESTINAL CANCERS:

Samuel Klempner, MD: The Role of the MATTERHORN Regimen in Resectable GC/GEJC

Dr. Samuel Klempner reviews key data from the MATTERHORN trial, which showed the benefit of perioperative durvalumab plus FLOT in the treatment of resectable gastric cancer/gastroesophageal function cancer. Dr. Klempner highlights EFS and OS gains with the MATTERHORN regimen, and briefly explores its role in clinical practice.

Haley Ellis, MD: Updated Efficacy Data from the TOPAZ-1 Clinical Trial

Learn how durvalumab plus gemcitabine/cisplatin improved long-term survival in the TOPAZ-1 trial, including new four-year overall survival data.

Midhun Malla, MD: Real-World Evidence and Emerging Frontline Therapies for Advanced Hepatocellular Carcinoma

Dr. Midhun Malla discusses the evolving treatment landscape for advanced unresectable hepatocellular carcinoma (HCC), highlighting the positive outcomes of the Phase 3 HIMALAYA trial and the STRIDE regimen of tremelimumab and durvalumab. He emphasizes that real-world evidence increasingly supports these novel immune checkpoint inhibitor combinations, while noting that ongoing trials like Sierra and LIVER-R are essential for evaluating their safety and efficacy in broader, more complex patient populations.